A new drug could lessen the effects of Duchenne Muscular Dystrophy, but some would say that it does little to help those who are already suffering the worst.
The drug, called Drisapersen, is a potential first treatment for Duchenne Muscular Dystrophy that targets an underlying cause of the condition. Pending approval by the U.S. Food and Drug Administration (FDA), the final decision over wether to release the drug onto the market has to be made by the end of December, two days after Christmas to be exact.
An advisory committee will review the drug prior to the FDA making their official decision.
Disapersen, applied via an under skin injection, will not cure Muscular Dystrophy but could potentially lessen the muscle weakness and atrophy caused by the condition.
This does little to help those who are already sick and potentially on their death bed due to the condition, but it is certainly a step in the right direction.